MGRX Financials

Income Statement
MetricQ3 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
69.5K
+2.4%
67.9K
-28.1%
94.4K
+12.0%
84.2K
-49.9%
168.1K
Cost of Revenue
8.8K
+7.2%
8.2K
-82.5%
46.9K
+1887.5%
2.4K
-97.0%
78.2K
Gross Profit
60.7K
+1.8%
59.6K
+25.6%
47.5K
-42.0%
81.9K
-9.0%
89.9K
Operating Expenses
3.7M
+101.3%
1.8M
+9.1%
1.7M
-78.2%
7.6M
+42.3%
5.4M
R&D
0
0
0
0
0
SG&A
3.0M
+101.2%
1.5M
-86.6%
11.2M
+59.3%
7.0M
+33.6%
5.3M
Operating Income
-3592716
-104.7%
-1755320
-8.6%
-1616002
+78.6%
-7542926
-43.2%
-5268495
EBITDA
-3592716
-145.4%
-1463732
-40.4%
-1042229
+86.2%
-7542926
-70.2%
-4432261
Net Income
-3553519
-4.4%
-3403141
-22.9%
-2769370
+63.7%
-7618776
-40.7%
-5415820
EPS (Basic)
$-0.19
+13.6%
$-0.22
-4.8%
$-0.21
+69.6%
$-0.69
-21.1%
$-0.57
EPS (Diluted)
$-0.19
+13.6%
$-0.22
-4.8%
$-0.21
+69.6%
$-0.69
-21.1%
$-0.57
Shares (Diluted)
20.4M
+23.9%
16.5M
+12.4%
14.7M
+27.3%
11.5M
+21.3%
9.5M
Mangoceuticals (MGRX) — Financials